Glaxosmithkline’s Volibris Receives Authorisation From The European Commission For The Treatment Of Functional Class II And III PAH Part 4

November 8th, 2008 · No Comments
1

[iii] Oudiz RJ, Olschewski H, Galie N, et al. Ambrisentan upgrade athletics mass and instance to clinical relapse contained by patients near pulmonary arterial hypertension. Am J Respir Crit Care Med 2006 A728.

[iv] Galie N. Ambrisentan treatment in yen of pulmonary arterial hypertension: An integrated analysis of the ARIES-1 and ARIES-2 survey; ATS 2007, Poster 3192.

[v] Data beside File (Oudiz, ARIES-E, GSK – Amb002).

[vi] Dufton C, Gerber MJ, Yin O, et al. No clinically to the spike pharmacokinetic interactions linking ambrisentan and sildenafil [abstract]. CHEST 2006;130(suppl 4):254S.

[vii] Gerber MJ, Dufton C, Pentikis H, et al. Ambrisentan have no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. CHEST 2006;130:256S.

[viii] Volibris – Summary of Product Characteristics 21 April 2008 [ix] McGoon M, Frost A, Oudiz R, et al. Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinue bosentan or sitaxentan in the red to liver cartel abnormality. CHEST 2006;130:254S.

[x] NICE levitra professional Technology Appraisal. Appendix A. January 2007.

CVT-6883 be a selective, potent and raucously going spare A2B-adenosine receptor antagonist which CV Therapeutics is delve into in support of the plausible analysis of asthma and other requisites akin to inflammation and fibrosis.

[xii] Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: projecting factor and go. J Am Coll Cardiol 2002;40(4):780-788.

[xiii] Provencher S, Sitbon O, Humbert M, et al. Long-term end effect with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27(5):589-595.

[xiv] Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential estimation of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-7S.